Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 2,169 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Exposure Clear all
Recruiting Not applicable Interventional

Point of Care STI Testing

NCT06844045
View directory record Official record
Conditions
Point of Care STI Testing
Interventions
Gonorrhea/chlamydia Point-of-Care Testing
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
16 Years to 24 Years
Enrollment
6,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 30, 2026, 3:48 PM EDT
Completed Phase 1 Interventional

Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg Ulcers

NCT02652572
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Granexin
Drug
Lead sponsor
Xequel Bio, Inc.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Augusta, Georgia • Spartanburg, South Carolina • Salem, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 30, 2026, 3:48 PM EDT
Terminated Not applicable Interventional Results available

Analysis of Lipid Biomarkers of Exposure and Host Response

NCT00493831
View directory record Official record
Conditions
Cigarette Smoking
Interventions
nicotine polacrilex, transdermal system or inhaler
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 30, 2026, 3:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Novel Determinants and Measures of Smokeless Tobacco Use: Study 1

NCT01067586
View directory record Official record
Conditions
Smokeless Tobacco Use, Tobacco Dependence
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
3
States / cities
Minneapolis, Minnesota • Eugene, Oregon • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 30, 2026, 3:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigating the Effect of Daily CARDIO® Capsules Supplementation on Improved Sleep in Healthy, Urban-Dwelling Adults

NCT06768970
View directory record Official record
Conditions
Sleep, Pollution; Exposure, Cough
Interventions
CARDIO® salmon oil
Dietary Supplement
Lead sponsor
Hofseth Biocare ASA
Industry
Eligibility
18 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 30, 2026, 3:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Singlet Oxygen Quantification After Skin Exposure to Ultraviolet A (UVA) Light

NCT05865431
View directory record Official record
Conditions
Sun Damaged Skin
Interventions
Zinc Oxide and Avobenzone
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 30, 2026, 3:48 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

NCT05319730
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Paclitaxel, Irinotecan, Pembrolizumab, MK-4830, Lenvatinib, Sacituzumab tirumotecan, Antihistamine, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent), Supportive care measures
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • East Syracuse, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 3:48 PM EDT
Completed Phase 2 Interventional Results available

Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)

NCT02628236
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
Aminolevulinic Acid (ALA), BLU-U
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 30, 2026, 3:48 PM EDT
Completed Phase 4 Interventional Results available

Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study

NCT01409434
View directory record Official record
Conditions
Drug Induced Hyperglycemia, Secondary Hyperlipidemia
Interventions
Oral Glucose Tolerance Test
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 30, 2026, 3:48 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Media Based Motivational Intervention to Prevent Alcohol Exposed Pregnancies (AEPs)

NCT00219336
View directory record Official record
Conditions
Alcohol Consumption, Fetal Alcohol Syndrome Disorders, Students
Interventions
Self-guided Motivational Intervention, Informational Only
Behavioral
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 30, 2026, 3:48 PM EDT
Completed No phase listed Observational Results available

Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

NCT02556775
View directory record Official record
Conditions
Exposure During Pregnancy
Interventions
A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment, HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 30, 2026, 3:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.

NCT05867212
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Injection [Apretude]
Drug
Lead sponsor
Kelley-Ross & Associates, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 30, 2026, 3:48 PM EDT
Not listed Not applicable Interventional

Effects of Green Light Exposure on Epileptic Spikes in Patients With Refractory Epilepsy

NCT03857074
View directory record Official record
Conditions
Epilepsy, Epilepsy Intractable
Interventions
Green Light Exposure
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 30, 2026, 3:48 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

NCT05540717
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Rhinoconjunctivitis
Interventions
PQ Grass, Placebo
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
33
States / cities
Centennial, Colorado • Denver, Colorado • Lexington, Kentucky + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 30, 2026, 3:48 PM EDT
Completed Not applicable Interventional

Imaginal Exposure II Study: In-Vivo

NCT03934697
View directory record Official record
Conditions
Eating Disorder, Anorexia Nervosa, Bulimia Nervosa, Exposure
Interventions
imaginal exposure therapy
Behavioral
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 30, 2026, 3:48 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infections (STI) Testing and PrEP Initiation Among Rural Men Who Have Sex With Men

NCT06205368
View directory record Official record
Conditions
HIV Infections, STI, HIV Pre-exposure Prophylaxis
Interventions
Combine mobile app, Motivational interview, HIV/STI testing
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
473 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 3:48 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Spinal Ketorolac After Acute Opioid Exposure

NCT00693160
View directory record Official record
Conditions
Healthy
Interventions
ketorolac, placebo, remifentanil, Capsaicin
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 30, 2026, 3:48 PM EDT
Completed No phase listed Observational

Molecular Epidemiology of Cutaneous Malignant Melanoma

NCT00341991
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
15,401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 30, 2026, 3:48 PM EDT
Completed No phase listed Observational

Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy

NCT01982591
View directory record Official record
Conditions
Male Breast Cancer, Neurotoxicity, Peripheral Neuropathy, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Paoli, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 30, 2026, 3:48 PM EDT
Completed Not applicable Interventional

Atenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers

NCT00607347
View directory record Official record
Conditions
Hypertension
Interventions
Glucose
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 30, 2026, 3:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nerve Damage in Patients With HIV Infection Who Have Been Treated With Anti-HIV Drugs

NCT00017771
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Oct 30, 2026, 3:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)

NCT02569632
View directory record Official record
Conditions
Meningococcal Infections
Interventions
Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)
Biological
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Oakland, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 30, 2026, 3:48 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination

NCT03350698
View directory record Official record
Conditions
Papillomavirus Vaccines
Interventions
Gardasil-9
Biological
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
27 Years to 69 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 30, 2026, 3:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Evaluation of the Photoallergy Potential of Atralin Gel

NCT00603772
View directory record Official record
Conditions
Healthy
Interventions
Atralin (tretinoin) gel, 0.05%
Drug
Lead sponsor
Coria Laboratories, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Oct 30, 2026, 3:48 PM EDT